Updates, Insights & Perspectives

Executive Summary For decades, oncology drug development has been measured through two dominant lenses: efficacy  and safety . While these remain essential, they no longer tell the full story of whether a therapy truly delivers value in real-world cancer care. An additional dimension — patient burden  — is now emerging as a critical determinant of therapeutic success, especially in populations such as non–small cell lung cancer (NSCLC), where most patients are elderly, medica

Executive Summary Stereotactic ablative radiotherapy (SABR) for early stage non–small cell lung cancer (NSCLC) and concurrent chemoradiation (CRT) for unresectable Stage III disease have become essential therapeutic backbones. SABR delivers highly focused, ablative radiation in a few fractions, while CRT provides integrated local and systemic treatment over several weeks. Both approaches are effective but constrained by persistent local progression, distant relapse, and treat

Executive Summary Global cancer care has become increasingly complex, expensive, and systemically burdensome. Despite remarkable innovations in molecular targets and immuno-oncology, many patients worldwide still face challenges linked not to the drug , but to the way drugs are delivered . Toxicity, accessibility, treatment interruptions, and limited applicability to older or medically fragile populations remain persistent barriers. Localized therapy — treatments that act dir

Executive Summary Non–small cell lung cancer (NSCLC) is shaped not only by the genetic characteristics of cancer cells but also by the complex environment surrounding them. This “tumor microenvironment” — consisting of stromal tissue, immune cells, vasculature, metabolic conditions, and oxygen availability — plays a major role in determining how tumors respond to radiotherapy. This article provides a high-level, non-technical overview of the key features of the NSCLC microenv

Executive Summary For years, precision medicine has been defined almost exclusively through the lens of genomic testing and targeted drugs. But as the field matures, a new reality is becoming clear: precision cannot be achieved through molecules alone . The next decade of innovation will belong to drug–device combinations — technologies that integrate therapeutic agents with delivery systems engineered to ensure the right dose reaches the right place at the right time. From n

Executive Summary Lung cancer care has evolved significantly over the past two decades, with major advances in radiotherapy, immunotherapy, and targeted systemic treatments. Yet real-world challenges remain. Many patients struggle with the cumulative burden of systemic therapy, and a large proportion of the NSCLC population cannot tolerate aggressive regimens due to age, comorbidities, or overall frailty. As oncology increasingly shifts toward precision, patient-centered care

Executive Summary For more than two decades, oncology innovation has been defined by the pursuit of new targets, new pathways, and new molecular entities. This model has delivered extraordinary breakthroughs — but it has also created diminishing returns, escalating costs, and widening gaps between scientific promise and real-world patient benefit. The next wave of oncology progress is unlikely to come from discovering ever more complex molecules. Instead, it will come from re

Summary Onconox Inc. has appointed Ajay Kambhampati as a Non-Executive Director. Ajay, one of the company’s original seed investors, brings more than 25 years of experience across healthcare technology, investment, and corporate finance. His strategic, financial, and operational expertise will support Onconox as it advances OCN001 through IND-enabling development and toward future clinical evaluation. Onconox Inc., a biotechnology company advancing a novel therapeutic candida